PB1404 - Impact of Tissue factor promoter gene polymorphism with Recurrent pregnancy loss in India.

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Presenting Author(s)

Kamal Kishor, PhD

Post Doctorate fellow
All India Institute of Medical Sciences
New Delhi, Delhi, India

Co-Author(s)

Amit Sharma, PhD

Post Doctoral Researcher
All India Institute of Medical Sciences
New Delhi, Delhi, India
SM

Samarjit Maharana

PhD Student
Blood and Vascular Biology Research Lab, Department of Life Sciences, School of Life Sciences, Central University of Tamil Nadu
Thiruvarur, Tamil Nadu, India
Chitrali Laha Roy, MSc

PhD Student
Blood and Vascular Biology Research Lab, Department of Life Sciences, School of Life Sciences, Central University of Tamil Nadu
Thiruvarur, Tamil Nadu, India
RR

Ravi Ranjan

Scientist
ALL INDIA INSTITUT OF MEDICAL SCIENCES, NEW DELHI
New Delhi, Delhi, India
rk

ravi kumar

Scientist
All India Institute of Medical Sciences
New Delhi, Delhi, India
MM

Manoranjan Mahapatra

Professor Of Hematology
AIIMS NEW DELHI
DELHI, Delhi, India
RS

Renu Saxena

Professor
Medanta - The Medicity Hospital, Gurgaon, India
Gurgaon, Haryana, India

Background: Recurrent pregnancy loss (RPL) is a common clinical anomaly resulting in repeated fetal loss and occurs with a frequency of 0.5–3 % in all couples trying to conceive. It is complex, multifactorial disease, and its etiology remains unexplained in 40-50 % of all RPL. Elevated level of tissue factor (TF) has been associated with DVT whereas, its association with Indian RPL patients is not yet studied.

Aims: To look for the association of TF with RPL in India and to elucidate the role of TF promoter gene polymorphism with TF plasma levels.

Methods: RPL patients with at least 3 consecutive pregnancy losses before 20 weeks of gestational age and equal number of healthy women with, at least one naturally conceived pregnancy were recruited for this study. Total 10 ml of whole blood was collected from each participant after obtaining proper informed consent. Plasma TF levels were determined by ELISA. TF promoter polymorphism 603A>G and prothrombotic mutations (Factor V Leiden and MTHFR 677C>T) were detected by PCR-RFLP.

Results: 70 RPL patients, median age 33 years range (21-44 years) were recruited. Mean plasma TF levels were significantly higher in patients than controls (74.85±12.30pg/ml and 69.95±12.15 pg/ml, respectively p=0.019). FV Leiden was significantly higher in patients 5 (7.1%) and absent in controls (p < 0.001). The distribution of MTHFR 677 C>T polymorphism was similar 12 (17.1%) in patients and 8 (11.4%) controls (p=0.46). AG and GG genotypes of 603 A>G polymorphism was significantly higher (31.4%) in patient than (15.7%) controls (p=0.046). Relation between the TF levels and their genotypes and relative risk of RPL are shown in table.

Conclusion(s): High TF level is significantly associated with Indian RPL patients. 603A>G polymorphism associated with high plasma TF level and 3.4-fold increases the risk of RPL. Thus, TF 603 A>G polymorphism detection may help in identifying high risk of DVT.